Altered Metabolic Integrity of Corpus Callosum Among Individuals at Ultra High Risk of Schizophrenia and First-Episode Patients

Biological Psychiatry

Volumn 64, Issue 9, 2008, Pages 750-757

  Aydin, Kubilay ^a   Ucok, Alp ^a   Guler, Julide ^b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Eyup State Hospital   (Turkey)

Author keywords

Corpus callosum; MR spectroscopy; N acetylaspartate; schizophrenia; ultra high risk

Indexed keywords

N ACETYLASPARTIC ACID; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; BRAIN DEVELOPMENT; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORPUS CALLOSUM; DEMOGRAPHY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HIGH RISK PATIENT; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; RISK ASSESSMENT; SCHIZOPHRENIA;

ADULT; ASPARTIC ACID; CASE-CONTROL STUDIES; CORPUS CALLOSUM; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PROTONS; PSYCHIATRIC STATUS RATING SCALES; RISK; SCHIZOPHRENIA; YOUNG ADULT;

EID: 53249115650     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2008.04.007     Document Type: Article

References (70)

1. Bloom F.E. Advancing a neurodevelopmental origin schizophrenia. Arch Gen Psychiatry 50 (1993) 224-227
2. Lieberman J.A., Perkins D., Belger A., Chakos M., Jarskog F., Boteva K., et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 50 (2001) 884-897
3. Burns J., Job D., Bastin M.E., Whalley H., Macgillivray T., Johnstone E.C., et al. Structural disconnectivity in schizophrenia: A diffusion tensor magnetic resonance imaging tensor magnetic study. Br J Psychiatry 182 (2003) 439-443
4. Crow T.J. Schizophrenia as a misconnection syndrome. Schizophr Res 30 (1998) 111-114
5. Friston K.J. The disconnection hypothesis. Schizophr Res 30 (1998) 115-125
6. Kanaan R.A., Kim J.S., Kaufmann W.E., Pearlson G.D., Barker G.J., and McGuire P.K. Diffusion tensor imaging in schizophrenia. Biol Psychiatry 58 (2005) 921-929
7. Kubicki M., Park H., Westin C.F., Nestor P.G., Mulkern R.V., Maier S.E., et al. DTI and MTR abnormalities in schizophrenia: Analysis of white matter integrity. Neuroimage 26 (2005) 1109-1118
8. Kubicki M., McCarley R.W., and Shenton M.E. Evidence for white matter abnormalities in schizophrenia. Curr Opin Psychiatry 18 (2005) 121-134
9. Walterfang M., Wood S.J., Velakoulis D., and Pantelis C. Neuropathological, neurogenetic and neuroimaging evidence for white matter pathology in schizophrenia. Neurosci Biobehav Rev 30 (2006) 918-948
10. Crow T.J., Ball J., Bloom S.R., Brown R., Bruton C.J., Colter N., et al. Schizophrenia as an anomaly of development of cerebral asymmetry. A post mortem study and a proposal concerning the genetic basis of the disease. Arch Gen Psychiatry 46 (1989) 1145-1150
11. DeLisi L.E., Sakuma M., Kushner M., Finer D.L., Hoff A.L., and Crow T.J. Anomalous cerebral asymmetry and language processing in schizophrenia. Schizophr Bull 23 (1997) 255-271
12. Mohr B., Pulvermüller F., Cohen R., and Rockstroh B. Interhemispheric cooperation during word processing: Evidence for callosal transfer dysfunction in schizophrenic patients. Schizophr Res 46 (2000) 231-239
13. Casanova M.F., Sanders R.D., and Goldberg T.E. Morphometry of the corpus callosum in monozygotic twins discordant for schizophrenia: A magnetic resonance imaging study. J Neurol Neurosurg Psychiatry 53 (1990) 416-421
14. Colombo C., Bonfanti A., and Scarone S. Anatomical characteristics of the corpus callosum and clinical correlates in schizophrenia. Eur Arch Psychiatry Clin Neurosci 243 (1994) 244-248
15. Hoff A., Neal C., Kushner M., and DeLisi L. Gender differences in corpus callosum size in first-episode schizophrenics. Biol Psychiatry 35 (1994) 913-919
16. Keshavan M.S., Diwadkar V.A., Harenski H., Rosenberg D.R., Sweeney J.A., and Pettegrew J.W. Abnormalities of the corpus callosum in first episode, treatment naive schizophrenia. J Neurol Neurosurg Psychiatry 72 (2002) 757-760
17. Raine A., Harrison G.N., Reynolds G.P., Sheard C., Cooper J.E., and Medley I. Structural and functional characteristics of the corpus callosum in schizophrenics, psychiatric controls, and normal controls. Arch Gen Psychiatry 47 (1990) 1060-1063
18. Woodruff P.W., Pearlson G., Geer M.J., Barta P.E., and Chilcoat H.D. A computerized magnetic resonance imaging study of corpus callosum morphology in schizophrenia. Psychol Med 23 (1993) 45-56
19. Woodruff P.W., McManus I.C., and David A.S. Meta-analysis of corpus callosum size in schizophrenia. J Neurol Neurosurg Psychiatry 58 (1995) 457-461
20. Downhill J.E., Buchsbaum M.S., Wei T., Spiegel-Cohen J., Hazlett E.A., Haznedar M.M., et al. Shape and size of the corpus callosum in schizophrenia and schizotypal personality disorder. Schizophr Res 42 (2000) 193-208
21. Tibbo P., Nopoulos P., Arndt S., and Andreasen N.C. Corpus callosum shape and size in male patients with schizophrenia. Biol Psychiatry 44 (1998) 405-412
22. Agartz I., Andersson J.L.R., and Skare S. Abnormal brain white matter in schizophrenia: A diffusion tensor imaging study. NeuroReport 12 (2001) 2251-2254
23. Ardekani B.A., Nierenberg J., Hoptman M.J., Javitt D.C., and Lim K.O. MRI study of white matter diffusion anisotropy in schizophrenia. NeuroReport 14 (2003) 2025-2029
24. Buchsbaum M.S., Friedman J., Buchsbaum B.R., Chu K.W., Hazlett E.A., Newmark R., et al. Diffusion tensor imaging in schizophrenia. Biol Psychiatry 60 (2006) 1181-1187
25. Hubl D., Koenig T., Strik W.K., Federspiel A., Kreis R., Boesch C., et al. Pathways that make voices: White matter changes in auditory hallucinations. Arch Gen Psychiatry 61 (2004) 658-668
26. Mitelman S.A., Torosjan Y., Newmark R.E., Schneiderman J.S., Chu K.W., Brickman A.M., et al. Internal capsule, corpus callosum and long associative fibers in good and poor outcome schizophrenia: A diffusion tensor imaging survey. Schizophr Res 92 (2007) 211-224
27. Shergill S.S., Kanaan R.A., Chitnis X.A., O'Daly O., Jones D.K., Frangou S., et al. A diffusion tensor imaging study of fasciculi in schizophrenia. Am J Psychiatry 164 (2007) 467-473
28. Buchsbaum M.S., Tang C.Y., Peled S., Gudbjartsson H., Lu D., Hazlett E.A., et al. MRI white matter diffusion anisotropy and PET metabolic rate in schizophrenia. NeuroReport 9 (1998) 425-430
29. Foong J., Symms M.R., Barker G.J., Maier M., Miller D.H., and Ron M.A. Investigating regional white matter in schizophrenia using diffusion tensor imaging. NeuroReport 13 (2002) 333-336
30. Kanaan R.A., Shergill S.S., Barker G.J., Catani M., Ng V.W., Howard R., et al. Tract-specific anisotropy measurements in diffusion tensor imaging. Psychiatry Res 146 (2006) 73-82
31. Price G., Bagary M.S., Cercignani M., Altmann D.R., and Ron M.A. The corpus callosum in first episode schizophrenia: A diffusion tensor imaging study. J Neurol Neurosurg Psychiatry 76 (2005) 585-587
32. Kumra S., Ashtari M., Cervellione K.L., Henderson I., Kester H., Roofeh D., et al. White matter abnormalities in early-onset schizophrenia: a voxel based diffusion tensor imaging study. J Am Acad Child Adolesc Psych 44 (2005) 934-941
33. Sun Z., Wang F., Cui L., Breeze J., Du X., Wang X., et al. Abnormal anterior cingulum in patients with schizophrenia: A diffusion tensor imaging study. NeuroReport 14 (2003) 1833-1836
34. Chard D.T., Griffin C.M., McLean M.A., Kapeller P., Kapoor R., Thompson A.J., et al. Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain 125 (2002) 2342-2352
35. Steel R.M., Bastin M.E., McConnell S., Marshall I., Cunningham-Owens D.G., Lawrie S.M., et al. Diffusion tensor imaging (DTI) and proton magnetic resonance spectroscopy (1H MRS) in schizophrenic subjects and normal controls. Psychiatry Res 106 (2001) 161-170
36. Bjartmar C., Battistuta J., Terada N., Dupree E., and Trap B.D. N-acetylaspartate is an axon-specific marker of mature white matter in vivo: A biochemical and immunohistochemical study on the rat optic nerve. Ann Neurol 51 (2002) 51-58
37. Aydin K., Ucok A., and Cakir S. Quantitative proton MR spectroscopy findings in the corpus callosum of patients with schizophrenia suggest callosal disconnection. AJNR Am J Neuroradiol 28 (2007) 1968-1974
38. McGlashan T.H. Early detection and intervention in schizophrenia. Schizophr Bull 22 (1996) 197-199
39. Yung A.R., and McGorry P.D. The initial prodrome in psychosis: Descriptive and qualitative aspects. Aust N Z J Psychiatry 30 (1996) 587-599
40. Miller T.J., McGlashan T.H., Rosen J.L., Somjee L., Markovich P.J., Stein K., et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the structured interview for prodromal syndromes: Preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry 159 (2002) 863-865
41. Yung A.R., Phillips L.J., McGorry P.D., McFarlane C.A., Francey S., Harrigan S., et al. Prediction of psychosis: A step towards indicated prevention of schizophrenia. Br J Psychiatry 172 (1998) 14-20
42. Yung A.R., McGorry P.D., McFarlane C.A., Jackson H.J., Patton G.C., and Rakkar A. Monitoring and care of young people at incipient risk of psychosis. Schizophr Bull 22 (1996) 283-303
43. McGorry P.D., McGorry A.R., Yung L.J., Phillips H.P., Yuen S., Francey E.M., et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 59 (2002) 921-928
44. Uçok A., Polat A., Genç A., Cakir S., and Turan N. Duration of untreated psychosis may predict acute treatment response in first-episode schizophrenia. J Psychiatr Res 38 (2004) 163-168
45. Uçok A., Polat A., Cakir S., and Genç A. One year outcome in first episode schizophrenia: Predictors of relapse. Eur Arch Psychiatry Clin Neurosci 256 (2006) 37-43
46. First M.B., Spitzer R.L., Gibbon M., and Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I disorders (SCID-I), Clinical Version (1997), American Psychiatric Press, Washington DC
47. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64 (2003) 663-667
48. Lukoff D., Nuechterlien K., and Ventura A. Manual for the expanded brief psychiatric rating scale. Schizophr Bull 12 (1986) 594-602
49. Andreasen N.C. The Scale for the Assessment of Positive Symptoms (SAPS) (1984), University of Iowa, Iowa City, IA
50. Andreasen N.C. The Scale for the Assessment of Negative Symptoms (SANS) (1983), University of Iowa, Iowa City, IA
51. Highley J.R., Esiri M.M., McDonald B., Cortina-Borja M., Herron B.M., and Crow T.J. The size and fibre composition of the corpus callosum with respect to gender and schizophrenia: A post-mortem study. Brain 122 (1999) 99-110
52. Witelson S.F. Hand and sex differences in the isthmus and genu of the human corpus callosum. Brain 112 (1989) 799-835
53. Keevil S.F., Barbiroli B., Brooks J.C., Cady E.B., Canese R., Carlier P., et al. Absolute metabolite quantification by in vivo NMR spectroscopy: II. A multicentre trial of protocols for in vivo localised proton studies of human brain. Magn Reson Imaging 16 (1998) 1093-1106
54. Cheong J.L.Y., Cady E.B., Penrice J., Wyatt J.S., Cox I.J., and Robertson N.J. Proton MR spectroscopy in neonates with perinatal cerebral hypoxic-ischemic injury: Metabolite peak-area ratios, relaxation times, and absolute concentrations. AJNR Am J Neuroradiol 27 (2006) 1546-1554
55. Michaelis T., Merboldt K.D., Bruhn H., Hanicke W., and Frahm J. Absolute concentrations of metabolites in the adult human brain in vivo: Quantification of localized proton MR spectra. Radiology 187 (1993) 219-227
56. Chard D.T., Parker G.J., Griffin C.M., Thompson A.J., and Miller D.H. The reproducibility and sensitivity of brain tissue volume measurements derived from an SPM-based segmentation methodology. J Magn Reson Imaging 15 (2002) 259-267
57. Miller B.L. A review of chemical issues in 1H NMR spectroscopy: N-acetyl-L-aspartate, creatine and choline. NMR Biomed 4 (1991) 47-52
58. Appenzeller S., Li L.M., Costallat L.T.L., and Cendes F. Evidence of reversible axonal dysfunction in systemic lupus erythematosus: A proton MRS study. Brain 128 (2005) 2933-2940
59. Najm I.M., Wang Y., Shedid D., Lüdees H.O., Nq T.C., and Comair Y.G. MRS metabolic markers of seizures and seizure-induced neuronal damage. Epilepsia 39 (1998) 244-250
60. Aydin K., Ciftci K., Terzibasioglu E., Ozkan M., Demirtas A., Sencer S., et al. Quantitative proton MR spectroscopic findings of cortical reorganization in the auditory cortex of musicians. AJNR Am J Neuroradiol 26 (2005) 128-136
61. Brambilla P., Cerini R., Gasparini A., Versace A., Andreone N., Vittorini E., et al. Investigation of corpus callosum in schizophrenia with diffusion imaging. Schizophr Res 79 (2005) 201-210
62. Rotarska-Jagiela A., Schönmeyer R., Oertel V., Haenschel C., Vogeley K., and Linden D.E. The corpus callosum in schizophrenia-volume and connectivity changes affect specific regions. NeuroImage 39 (2008) 1522-1532
63. Flynn S.W., Lang D.J., Mackay A.L., Goghari V., Vavasour I.M., Whittall K.P., et al. Abnormalities of myelination in schizophrenia detected in vivo with MRI, and post-mortem with analysis of oligodendrocyte proteins. Mol Psychiatry 8 (2003) 811-820
64. Hakak Y., Walker J.R., Li C., Wong W.H., Davis K.L., Buxbaum J.D., et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A 98 (2001) 4746-4751
65. Uranova N., Orlovskaya D., Vikhreva O., Zimina I., Kolomeets N., Vostrikov V., et al. Electron microscopy of oligodendroglia in severe mental illness. Brain Res Bull 55 (2001) 597-610
66. Peirce T.R., Bray N.J., Williams N.M., Norton N., Moskvina V., Preece A., et al. Convergent evidence for 2′,3′-cyclic nucleotide 3′-phosphodiesterase as a possible susceptibility gene for schizophrenia. Arch Gen Psychiatry 63 (2006) 18-24
67. Foong J., Symms M.R., Barker G.J., Maier M., Woermann F.G., Miller D.H., et al. Neuropathological abnormalities in schizophrenia: Evidence from magnetization transfer imaging. Brain 124 (2001) 882-892
68. Bertolino A., Callicott J.H., Mattay V.S., Weidenhammer K.M., Rakow R., Egan M.F., et al. The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia. Biol Psychiatry 49 (2001) 39-46
69. Bustillo J.R., Lauriello J., Rowland L.M., Thomson L.M., Petropoulos H., Hammond R., et al. Longitudinal follow-up of neurochemical changes during the first year of antipsychotic treatment in schizophrenia patients with minimal previous medication exposure. Schizophr Res 58 (2002) 313-321
70. Yücel M., Harrison B.J., Wood S.J., Fornito A., Clarke K., Wellard R.M., et al. State, trait and biochemical influences on human anterior cingulate function. Neuroimage 34 (2007) 1766-1773